Imipenem Mixture w/ Cilastin (syn: Imipenem/Cilastin) is a 1:1 mixture of Imipenem and Cilastin, a combination originally developed by Merck & Co. in 1985 under the trade name Primaxin.
Imipenem is a broad-spectrum carbapenem that is effective against extended spectrum β-lactamase (ESBL) producing Enterobacteriaceae, a group of pathogenic microbes resistant to many first line β-lactam antibiotics and certain cephalosporins. Cilastatin is a chemical substance which inhibits dehydropeptidase (DHP1), a human enzyme that degrades Imipenem.
Imipenem Mixture w/ Cilastin is soluble in aqueous solution.
We also offer:
- Imipenem (I001)
|Mechanism of Action||β-lactams interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBP’s are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to β-lactams is commonly due to cells containing plasmid encoded β-lactamases. Like many members of the carbapenem subgroup, imipenem is highly resistant to β-lactamase activity.|
|Spectrum||Imipenem is a broad-spectrum antibiotic targeting a wide range of aerobic and anaerobic Gram-positive and Gram-negative bacteria.|
|Microbiology Applications||Imipenem is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative MIC values include:
For a representative list of Imipenem MIC values, click here.
|Plant Biology Applications||Imipenem has been shown to be effective against bacteria from the genus Burkholderia, a well-described plant pathogen. It has also been shown to be effective for sour skin (onions), slippery skin (bulbs), and cavity disease (mushrooms)(Sojanova et al, 2007).|
|Molecular Formula||C12H17N3O4S • H2O ; C16H26N2O5S|
|Assay||Imipenem: ≥ 400 µg/mg
Cilastatin: ≥ 400 µg/mg
Imipenem:Cilastatin: 0.95 - 1.05: 1
|Loss on drying||
Not more tha5%
Berg PH, Voit EO and White RL (1996) A pharmacodynamic model for the action of the antibiotic Imipenem on Pseudomonas aeruginosa populations in vitro. Bltn. Mathcal. Biol. 58(5):923-938
Chen P et al (2014) Activity of Imipenem against Klebsiella pneumoniae biofilms in vitro and in vivo. Antimicrob. Agents Chemother. 58(2):1208-1213
Lyon JA (1985) Imipenem/cilastatin: The first carbapenem antibiotic. Drug Intell Clin Pharm. 19(12):895‐899
Pitout JD, Sanders CC, Sanders WE (1997) Antimicrobial resistance with focus on beta-lactam resistance in Gram-negative bacilli. Am J Med 103:51
|MIC||Stenotrophomonas maltophilia (TOT16)| 512 － ?| 659| Stenotrophomonas maltophilia (TOT19)| 256 － ?| 659| Stenotrophomonas maltophilia (TOT43)| 256 － ?| 659| Stenotrophomonas maltophilia (TOT57)| 256 － ?| 659| Stenotrophomonas maltophilia (TOT8)| 512 － ?| 659||